ArticleNature medicine2018
A potential biomarker for anti-PD-1 immunotherapy.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The application of peripheral blood immune profiling in personalized treatment of locally advanced and advanced lung cancer: a nomogram approach.Frontiers in oncology · 2025Article
- Organoid co-culture models of the tumor microenvironment promote precision medicine.Cancer innovation · 2024Review
- Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.Molecular cancer · 2023Article
- Recent advances in sonodynamic immunotherapy.Journal of cancer research and clinical oncology · 2023Review
- Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.Biomedicines · 2022Review
- A Novel Strategy to Identify Haematology Patients at High Risk of Developing Aspergillosis.Frontiers in immunology · 2021Observational
- The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.Neuro-oncology · 2020Article
- Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.The pharmacogenomics journal · 2020Review
- Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies.Frontiers in cell and developmental biology · 2020Review
- The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.Frontiers in immunology · 2019Review
- DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade.Frontiers in genetics · 2019Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29414936What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.